Compass Therapeutics (CMPX) Amortization of Deferred Charges (2019 - 2026)
Compass Therapeutics (CMPX) reported Amortization of Deferred Charges of $353000.0 for Q1 2026, up 57.59% on a YoY basis from $224000.0 in Q1 2025, and little changed sequentially from $353000.0 in Q4 2025.
Compass Therapeutics (CMPX) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Compass Therapeutics (CMPX) has 8 years of Amortization of Deferred Charges data on file, last reported at $353000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 57.59% year-over-year to $353000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 22.8% YoY), and the FY2025 full-year result was $1.2 million, up 2.75% from the prior year.
- Amortization of Deferred Charges steadied at $353000.0 in Q1 2026, from $353000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $353000.0 in Q4 2025 to a low of $219000.0 in Q4 2024.
- A 5-year average of $295647.1 and a median of $295000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges fell 28.66% in 2024 and soared 61.19% in 2025, its largest moves.
- Tracing CMPX's Amortization of Deferred Charges over 5 years: stood at $289000.0 in 2022, then rose by 6.23% to $307000.0 in 2023, then slipped by 28.66% to $219000.0 in 2024, then soared by 61.19% to $353000.0 in 2025, then changed by 0.0% to $353000.0 in 2026.
- Business Quant data shows CMPX's Amortization of Deferred Charges at $353000.0 in Q1 2026, $353000.0 in Q4 2025, and $352000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 353,000.00 |
| Mar 31, 2026 | 353,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Dec 31, 2025 | 353,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 314,000.00 |
| Jun 30, 2024 | 314,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Dec 31, 2023 | 307,000.00 |